Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.

Next Previous
Search
Trial Profile

A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cebranopadol (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Tris Pharma

    • Most Recent Events

    • 16 Jun 2017 A population PK analysis of cebranopadol using data from phase I and II trials, results published in the Clinical Pharmacokinetics
    • 05 Jun 2012 Actual patient number (189) added as reported by ClinicalTrials.gov.
    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2010-022557-42).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top